---
title: "Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis | OCS Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281146823.md"
description: "Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis | OCS Stock News"
datetime: "2026-03-31T00:01:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281146823.md)
  - [en](https://longbridge.com/en/news/281146823.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281146823.md)
generator: "portal-rs"
---

# Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis | OCS Stock News

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis | OCS Stock News

### Related Stocks

- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)
- [OCS.US](https://longbridge.com/en/quote/OCS.US.md)
- [OCSAW.US](https://longbridge.com/en/quote/OCSAW.US.md)

## Related News & Research

- [Legal & General Group Plc Takes $1.16 Million Position in Ocular Therapeutix, Inc. $OCUL](https://longbridge.com/en/news/298278897.md)
- [Ocular Therapeutix joins Baird Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297641301.md)
- [Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset](https://longbridge.com/en/news/296129081.md)
- [Oculis To Acquire Rights To Privosegtor, ACT-02 From Accure Therapeutics; Shares Up](https://longbridge.com/en/news/295380758.md)
- [Oculis directors vest and settle RSUs, filings show](https://longbridge.com/en/news/295969673.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**